Genmab Signs Agreement with DSM Biologics to Produce Clinical and Commercial Supply of HuMax-CD4
Copenhagen, Denmark: Genmab A/S announced it has signed an agreement with DSM Biologics to produce a commercial supply of HuMax-CD4, Genmab's antibody for the treatment of T-cell lymphoma. DSM will manufacture c-GMP batches of HuMax-CD4 for clinical trials and subsequent commercial supply. The material will be produced in DSM's facility in Groningen, the Netherlands.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.